Quarterly ResultNov 6, 2026, 08:51 AM
CG Oncology Reports Q3 Loss of $56.9M on $1.6M Revenue
AI Summary
CG Oncology, Inc. filed its 10-Q report for the period ending September 30, 2026. The company reported total revenues of $1.604 million for the third quarter, a slight increase year-over-year. However, the net loss widened to $56.891 million from $43.808 million in the same period last year, primarily driven by increased research and development expenses. Total assets grew significantly to $1.047 billion, largely due to an increase in marketable securities, while cash and cash equivalents saw a decrease.
Key Highlights
- CG Oncology reported total revenues of $1.604 million for the three months ended September 30, 2026, a slight increase from $1.508 million in the prior year period.
- Net loss for the three months ended September 30, 2026, was $56.891 million, compared to a net loss of $43.808 million for the same period in 2025.
- Research and development expenses increased to $39.221 million for the three months ended September 30, 2026, from $27.884 million in the prior year.
- Total assets grew to $1.047 billion as of September 30, 2026, up from $791.592 million as of December 31, 2025.
- Marketable securities significantly increased to $956.211 million from $709.665 million.
- Cash and cash equivalents decreased to $28.247 million from $32.490 million.
- Total liabilities increased to $55.704 million from $38.990 million.
- Stockholders' equity increased to $990.966 million from $752.602 million.
Price Impact
More from CGON